Life sciences commercialisation provider Indegene Limited has announced its unaudited consolidated financial results for the first quarter ended June 30, 2026 (Q1 FY27). The company demonstrated robust operational momentum, with quarterly revenue from operations expanding by 39.73% year-on-year.
Financial Performance Summary
Indegene recorded Revenue from Operations of ₹10,631 million for Q1 FY27, compared to ₹7,608 million in the corresponding quarter of the previous fiscal year (Q1 FY26) and ₹10,034 million in the preceding quarter (Q4 FY26). Supplemented by net other income of ₹290 million, Total Income reached ₹10,921 million, up from ₹7,829 million in Q1 FY26 and ₹10,142 million in Q4 FY26.
The company's Net Profit After Tax (PAT) stood at ₹1,162 million for the quarter, remaining steady compared to ₹1,164 million recorded in Q1 FY26, while surging 45.80% sequentially from ₹797 million in Q4 FY26.
Total Comprehensive Income for Q1 FY27 stood at ₹1,280 million, supported by ₹118 million in net Other Comprehensive Income (OCI). The OCI included ₹97 million from foreign currency translation differences and ₹58 million in net gain on cash flow hedges, offset by remeasurement losses on defined benefit obligations and deferred tax impact.
Operating Expense Breakdown
Total expenses for Q1 FY27 stood at ₹9,394 million, up from ₹6,308 million in Q1 FY26 and ₹8,888 million in Q4 FY26. The increase was primarily driven by:
Employee Benefits Expense: Rose to ₹6,591 million (vs. ₹4,815 million in Q1 FY26 and ₹6,324 million in Q4 FY26).
Other Expenses: Advanced to ₹2,298 million (vs. ₹1,240 million in Q1 FY26 and ₹2,074 million in Q4 FY26).
Depreciation & Amortisation: Measured at ₹441 million (vs. ₹216 million in Q1 FY26).
Finance Costs: Stood at ₹64 million (vs. ₹37 million in Q1 FY26).
Profit Before Tax (PBT) for the quarter came in at ₹1,527 million, matching the ₹1,521 million recorded in Q1 FY26 and growing from ₹1,051 million in Q4 FY26 (which included an exceptional charge of ₹203 million). Total tax expense for Q1 FY27 amounted to ₹365 million, consisting of current tax of ₹293 million and deferred tax of ₹72 million.
Segment-Wise Operational Performance
Enterprise Commercial Solutions
Segment Revenue: Expanded 43.96% YoY to ₹7,502 million, up from ₹5,211 million in Q1 FY26 and ₹7,193 million in Q4 FY26.
Segment Results: Delivered ₹1,197 million, compared to ₹1,099 million in Q1 FY26 and ₹1,212 million in Q4 FY26.
Enterprise Medical Solutions
Segment Revenue: Grew 28.33% YoY to ₹2,736 million, compared to ₹2,132 million in Q1 FY26 and ₹2,537 million in Q4 FY26.
Segment Results: Advanced 24.31% YoY to ₹716 million, up from ₹576 million in Q1 FY26 and ₹672 million in Q4 FY26.
Others (Consultancy and Clinical Business)
Segment Revenue: Stood at ₹393 million, compared to ₹265 million in Q1 FY26 and ₹304 million in Q4 FY26.
Segment Results: Recorded a loss of ₹(115) million, narrowing sequentially from ₹(163) million in Q4 FY26, compared to ₹(50) million in Q1 FY26.
Total Segment Results before unallocable expenses, depreciation, net finance cost, and tax stood at ₹1,798 million for the quarter.
Earnings Per Share & Equity Structure
Basic Earnings Per Share (EPS): Recorded at ₹4.84 per share for Q1 FY27 (face value of ₹2.00 each, not annualised), compared to ₹4.86 in Q1 FY26 and ₹3.32 in Q4 FY26.
Diluted Earnings Per Share (EPS): Stood at ₹4.81 per share, compared to ₹4.82 in Q1 FY26 and ₹3.30 in Q4 FY26.
Paid-Up Equity Share Capital: Remained at ₹481 million (face value of ₹2.00 per share).
Other Equity: Stood at ₹30,906 million as of March 31, 2026.
Shares of Indegene Limited was last trading in BSE at Rs. 514.50 as compared to the previous close of Rs. 523.65. The total number of shares traded during the day was 30668 in over 2310 trades.
The stock hit an intraday high of Rs. 538.55 and intraday low of 510.00. The net turnover during the day was Rs. 16088454.00.